Olaparib is the first PARP inhibitor targeting mainly PARP 1 and 2 approved by the FDA to treat advanced ovarian cancer patients with germline BRCA mutations and is widely studied in combination with DNA damage-induced drugs or radiotherapy. Here, PARP1 is linked to ovarian cancer.